WEKO3
アイテム
{"_buckets": {"deposit": "8a44add9-3d8e-4e0a-9a1b-f02112b852fe"}, "_deposit": {"created_by": 6, "id": "3858", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "3858"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00003858", "sets": ["24"]}, "author_link": ["115523", "115522"], "item_5_alternative_title_19": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "ゲフィチニブの薬物動態パラメーターと無増悪生存期間・有害事象との相関"}]}, "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-02-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "382", "bibliographicPageStart": "377", "bibliographicVolumeNumber": "78", "bibliographic_titles": [{"bibliographic_title": "Cancer Chemotherapy and Pharmacology"}]}]}, "item_5_date_granted_64": {"attribute_name": "学位授与年月日", "attribute_value_mlt": [{"subitem_dategranted": "2017-02-01"}]}, "item_5_degree_grantor_62": {"attribute_name": "学位授与機関", "attribute_value_mlt": [{"subitem_degreegrantor": [{"subitem_degreegrantor_name": "Nagasaki University (長崎大学)"}], "subitem_degreegrantor_identifier": [{"subitem_degreegrantor_identifier_name": "17301", "subitem_degreegrantor_identifier_scheme": "kakenhi"}]}]}, "item_5_degree_name_61": {"attribute_name": "学位名", "attribute_value_mlt": [{"subitem_degreename": "博士(医学)"}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Patients and methods: \nPlasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib \nwere also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib. Results: The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8. The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h. The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days. A high D8/D2 ratio was significantly correlated with better PFS, though the plasma trough levels on D2 and D8 were not significantly related to PFS. The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events. Pharmacokinetic parameters were not significantly correlated with OS. Conclusions: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. On the other hand, long elimination half-life was related to high-grade adverse events in these patients.", "subitem_description_type": "Abstract"}]}, "item_5_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "長崎大学学位論文 学位記番号:博(医歯薬)甲第914号 学位授与年月日:平成29年2月1日", "subitem_description_type": "Other"}]}, "item_5_description_69": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Nagasaki University (長崎大学), 博士(医学) (2017-02-01)", "subitem_description_type": "Other"}]}, "item_5_dissertation_number_65": {"attribute_name": "学位授与番号", "attribute_value_mlt": [{"subitem_dissertationnumber": "甲医歯薬第914号"}]}, "item_5_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "115523", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Mizoguchi, Kosuke"}]}]}, "item_5_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer"}]}, "item_5_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s00280-016-3097-4", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c Springer-Verlag Berlin Heidelberg 2016"}, {"subitem_rights": "The final publication is available at link.springer.com"}]}, "item_5_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03445704", "subitem_source_identifier_type": "ISSN"}]}, "item_5_text_67": {"attribute_name": "学位の種類", "attribute_value_mlt": [{"subitem_text_value": "課程博士"}]}, "item_5_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "溝口, 孝輔"}], "nameIdentifiers": [{"nameIdentifier": "115522", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-02-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ISYK914_Mizoguchi.pdf", "filesize": [{"value": "137.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 137100.0, "url": {"label": "ISYK914_Mizoguchi.pdf", "objectType": "fulltext", "url": "https://nagasaki-u.repo.nii.ac.jp/record/3858/files/ISYK914_Mizoguchi.pdf"}, "version_id": "47ea81c8-6c60-4742-ab1f-df8cc096e4a3"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "EGFR mutations", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Elimination half-life", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Gefitinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-small cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pharmacokinetics", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "doctoral thesis", "resourceuri": "http://purl.org/coar/resource_type/c_db06"}]}, "item_title": "Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations", "subitem_title_language": "en"}]}, "item_type_id": "5", "owner": "6", "path": ["24"], "permalink_uri": "http://hdl.handle.net/10069/37043", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2017-02-06"}, "publish_date": "2017-02-06", "publish_status": "0", "recid": "3858", "relation": {}, "relation_version_is_last": true, "title": ["Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations"], "weko_shared_id": -1}
Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations
http://hdl.handle.net/10069/37043
http://hdl.handle.net/10069/370434fe78e31-4e99-4bf8-bc6c-e0fe887c257a
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学位論文 / Thesis or Dissertation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-02-06 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Chemotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | EGFR mutations | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Elimination half-life | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Gefitinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Non-small cell lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Pharmacokinetics | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||
資源タイプ | doctoral thesis | |||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
著者 |
溝口, 孝輔
× 溝口, 孝輔 |
|||||
著者別名 | ||||||
姓名 | Mizoguchi, Kosuke | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Patients and methods: Plasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib were also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib. Results: The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8. The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h. The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days. A high D8/D2 ratio was significantly correlated with better PFS, though the plasma trough levels on D2 and D8 were not significantly related to PFS. The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events. Pharmacokinetic parameters were not significantly correlated with OS. Conclusions: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. On the other hand, long elimination half-life was related to high-grade adverse events in these patients. |
|||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 長崎大学学位論文 学位記番号:博(医歯薬)甲第914号 学位授与年月日:平成29年2月1日 | |||||
書誌情報 |
Cancer Chemotherapy and Pharmacology 巻 78, 号 2, p. 377-382, 発行日 2017-02-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 03445704 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s00280-016-3097-4 | |||||
権利 | ||||||
権利情報 | c Springer-Verlag Berlin Heidelberg 2016 | |||||
権利 | ||||||
権利情報 | The final publication is available at link.springer.com | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
その他のタイトル | ||||||
その他のタイトル | ゲフィチニブの薬物動態パラメーターと無増悪生存期間・有害事象との相関 | |||||
出版者 | ||||||
出版者 | Springer | |||||
学位名 | ||||||
学位名 | 博士(医学) | |||||
学位授与機関 | ||||||
学位授与機関識別子Scheme | kakenhi | |||||
学位授与機関識別子 | 17301 | |||||
学位授与機関名 | Nagasaki University (長崎大学) | |||||
学位授与年月日 | ||||||
学位授与年月日 | 2017-02-01 | |||||
学位授与番号 | ||||||
学位授与番号 | 甲医歯薬第914号 | |||||
学位の種類 | ||||||
課程博士 | ||||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Nagasaki University (長崎大学), 博士(医学) (2017-02-01) |